Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

ClinicalTrials.gov ID: NCT06921785

Public ClinicalTrials.gov record NCT06921785. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 13, 2026, 10:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy

Study identification

NCT ID
NCT06921785
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
1,220 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 5, 2025
Primary completion
Mar 14, 2030
Completion
Mar 14, 2030
Last update posted
Sep 2, 2026

2025 – 2030

United States locations

U.S. sites
36
U.S. states
22
U.S. cities
33
Facility City State ZIP Site status
Research Site Phoenix Arizona 85054 Recruiting
Research Site Tucson Arizona 85719 Recruiting
Research Site Los Angeles California 90095 Recruiting
Research Site Palo Alto California 94304 Recruiting
Research Site New Haven Connecticut 06520 Recruiting
Research Site Newark Delaware 19713 Recruiting
Research Site Jacksonville Florida 32224 Recruiting
Research Site Orlando Florida 32804 Not yet recruiting
Research Site Atlanta Georgia 30318 Recruiting
Research Site Atlanta Georgia 30322 Withdrawn
Research Site Honolulu Hawaii 96813 Withdrawn
Research Site Chicago Illinois 60637 Recruiting
Research Site Indianapolis Indiana 46202 Not yet recruiting
Research Site Shreveport Louisiana 71103 Not yet recruiting
Research Site Detroit Michigan 48202 Recruiting
Research Site Grand Rapids Michigan 49503 Recruiting
Research Site Rochester Minnesota 55905 Recruiting
Research Site St Louis Missouri 63110 Not yet recruiting
Research Site New Brunswick New Jersey 08901 Recruiting
Research Site New York New York 10029 Recruiting
Research Site New York New York 10032 Recruiting
Research Site New York New York 10065 Not yet recruiting
Research Site Cleveland Ohio 44195 Withdrawn
Research Site Oklahoma City Oklahoma 73104 Not yet recruiting
Research Site Philadelphia Pennsylvania 19107 Not yet recruiting
Research Site Pittsburgh Pennsylvania 15232 Recruiting
Research Site Amarillo Texas 79124 Recruiting
Research Site Austin Texas 78705 Recruiting
Research Site Dallas Texas 75390 Withdrawn
Research Site Houston Texas 77030 Recruiting
Research Site San Antonio Texas 78240 Recruiting
Research Site Tyler Texas 75702 Recruiting
Research Site Arlington Virginia 22201 Recruiting
Research Site Salem Virginia 24153 Recruiting
Research Site Seattle Washington 98101 Recruiting
Research Site Milwaukee Wisconsin 53226 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 182 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06921785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 2, 2026 · Synced Sep 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06921785 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →